Value of bevacizumab in the first-line treatment of epithelial ovarian cancer in the era of precision medicine

DAI Guanlin; TANG Furong; WANG Danqing

doi:10.3969/j.issn.2096-3351.2023.03.005

您当前的位置：

首页 >

文章列表页 >

Value of bevacizumab in the first-line treatment of epithelial ovarian cancer in the era of precision medicine

更新时间：2023-05-25

- Value of bevacizumab in the first-line treatment of epithelial ovarian cancer in the era of precision medicine
- Journal of Southwest Medical University Vol. 46, Issue 3, Pages: 208-212(2023)
- 作者机构：
  
  1. 四川大学华西第二医院妇产科,成都,610041
  2. 出生缺陷与相关妇儿疾病教育部重点实验室,成都,610041
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.2096-3351.2023.03.005
  CLC：
- Published：2023，
  
  Published Online：20 May 2023，
扫描看全文
DAI Guanlin, TANG Furong, WANG Danqing. Value of bevacizumab in the first-line treatment of epithelial ovarian cancer in the era of precision medicine. [J]. Journal of Southwest Medical University 46(3):208-212(2023)
DOI：

DAI Guanlin, TANG Furong, WANG Danqing. Value of bevacizumab in the first-line treatment of epithelial ovarian cancer in the era of precision medicine. [J]. Journal of Southwest Medical University 46(3):208-212(2023) DOI： 10.3969/j.issn.2096-3351.2023.03.005.

摘要

上皮性卵巢癌是妇科常见的恶性肿瘤，由于缺乏早期的筛查手段，发现时往往已为晚期，其复发率高，5 年生存率低，仅40% 左右。上皮性卵巢癌规范治疗非常重要，满意的肿瘤细胞减灭术、以铂类为基础的联合化疗以及维持治疗是上皮性卵巢癌患者获益的基石和关键。随着靶向治疗及免疫治疗等精准医疗手段的飞速发展，贝伐珠单抗在上皮性卵巢癌一线治疗中的价值如何？本文通过梳理贝伐珠单抗在上皮性卵巢癌一线治疗中的重要临床研究及进展，探寻它在上皮性卵巢癌一线治疗中的地位和作用，为该类患者的临床选择提供依据。

Abstract

Epithelial ovarian cancer is a common malignant tumor in gynecology.Due to the lack of early screening tools，it is gen⁃ erally found at an advanced stage，with high rate of recurrence and low 5-year survival rate hovering around 40%.Standard treatment is extremely important，and satisfactory cytoreductive surgery，platinum-based combination chemotherapy，and maintenance therapy are the cornerstones and keys to benefit patients with epithelial ovarian cancer.With the rapid development of precision medicine such as targeted therapy and immunotherapy，what is the value of bevacizumab in the first-line treatment of epithelial ovarian cancer? This pa⁃ per explored the status and role of bevacizumab in the first-line treatment of epithelial ovarian cancer by sorting out the important clini⁃ cal studies and progress in the first line treatment and provided basis for the clinical selection of epithelial ovarian cancer patients.

关键词

上皮性卵巢癌精准医疗靶向治疗贝伐珠单抗抗血管生存治疗

Keywords

Epithelial ovarian cancerPrecision medicineTargeted therapyBevacizumabAnti-angiogenic therapy

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research on natural biomimetic nano-drug delivery system for treatment of rheumatoid arthritis

Advances in the study of immune cell changes after ischemic stroke

Progress in multimodality therapy for primary hepatocellular carcinoma unsuitable for surgery

Related Author

审校

李春红

综述

聂宇

刘妍

王成龙

贾铭

郑秀

Related Institution

Department of Pharmaceutical Sciences，School of Pharmacy，Southwest Medical University

School of Biomedical Engineering，Sichuan University

Department of Cardioencephalopathy,Traditional Chinese Medicine Hospital Attached to Southwest Medical University

Academic Affairs Office of Southwest Medical University

Southwestern Medical University

⁰